Annual FCF
-$29.24 M
-$29.89 M-4626.32%
31 December 2023
Summary:
Lineage Cell Therapeutics annual free cash flow is currently -$29.24 million, with the most recent change of -$29.89 million (-4626.32%) on 31 December 2023. During the last 3 years, it has fallen by -$9.42 million (-47.55%). LCTX annual FCF is now -4626.32% below its all-time high of $646.00 thousand, reached on 31 December 2022.LCTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$5.90 M
-$673.00 K-12.88%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly free cash flow is currently -$5.90 million, with the most recent change of -$673.00 thousand (-12.88%) on 30 September 2024. Over the past year, it has dropped by -$723.00 thousand (-13.97%). LCTX quarterly FCF is now -126.99% below its all-time high of $21.86 million, reached on 31 March 2022.LCTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$23.06 M
-$723.00 K-3.24%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM free cash flow is currently -$23.06 million, with the most recent change of -$723.00 thousand (-3.24%) on 30 September 2024. Over the past year, it has increased by +$8.36 million (+26.61%). LCTX TTM FCF is now -527.60% below its all-time high of $5.39 million, reached on 31 March 2022.LCTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4626.3% | -14.0% | +26.6% |
| 3 y3 years | -47.5% | -20.0% | +2.1% |
| 5 y5 years | +14.4% | +21.5% | +31.6% |
LCTX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -4626.3% | at low | -127.0% | +48.4% | -527.6% | +29.4% |
| 5 y | 5 years | -4626.3% | +14.4% | -127.0% | +48.4% | -527.6% | +31.6% |
| alltime | all time | -4626.3% | +41.4% | -127.0% | +61.1% | -527.6% | +58.5% |
Lineage Cell Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.90 M(+12.9%) | -$23.06 M(+3.2%) |
| June 2024 | - | -$5.23 M(-10.2%) | -$22.33 M(-5.5%) |
| Mar 2024 | - | -$5.82 M(-4.7%) | -$23.63 M(-19.2%) |
| Dec 2023 | -$29.24 M(-4626.3%) | -$6.11 M(+18.0%) | -$29.24 M(-6.9%) |
| Sept 2023 | - | -$5.18 M(-20.7%) | -$31.42 M(-1.8%) |
| June 2023 | - | -$6.52 M(-42.9%) | -$32.01 M(-1.9%) |
| Mar 2023 | - | -$11.43 M(+37.9%) | -$32.64 M(-5152.9%) |
| Dec 2022 | $646.00 K(-102.7%) | -$8.29 M(+43.7%) | $646.00 K(-77.8%) |
| Sept 2022 | - | -$5.77 M(-19.5%) | $2.91 M(-22.6%) |
| June 2022 | - | -$7.16 M(-132.8%) | $3.76 M(-30.2%) |
| Mar 2022 | - | $21.86 M(-463.2%) | $5.39 M(-122.6%) |
| Dec 2021 | -$23.90 M(+20.6%) | -$6.02 M(+22.4%) | -$23.90 M(+1.5%) |
| Sept 2021 | - | -$4.92 M(-11.1%) | -$23.55 M(+0.2%) |
| June 2021 | - | -$5.53 M(-25.6%) | -$23.50 M(+5.8%) |
| Mar 2021 | - | -$7.43 M(+31.2%) | -$22.22 M(+12.1%) |
| Dec 2020 | -$19.82 M(-38.8%) | -$5.67 M(+16.3%) | -$19.82 M(+0.7%) |
| Sept 2020 | - | -$4.87 M(+14.7%) | -$19.68 M(-11.8%) |
| June 2020 | - | -$4.25 M(-15.7%) | -$22.32 M(-20.1%) |
| Mar 2020 | - | -$5.04 M(-8.9%) | -$27.94 M(-13.7%) |
| Dec 2019 | -$32.39 M(-5.2%) | -$5.53 M(-26.4%) | -$32.39 M(-3.9%) |
| Sept 2019 | - | -$7.51 M(-23.8%) | -$33.69 M(-3.0%) |
| June 2019 | - | -$9.86 M(+4.0%) | -$34.74 M(+7.5%) |
| Mar 2019 | - | -$9.48 M(+38.9%) | -$32.32 M(-5.4%) |
| Dec 2018 | -$34.17 M(+7.3%) | -$6.83 M(-20.3%) | -$34.17 M(+2.3%) |
| Sept 2018 | - | -$8.57 M(+15.1%) | -$33.41 M(+1.3%) |
| June 2018 | - | -$7.44 M(-34.4%) | -$32.98 M(-5.4%) |
| Mar 2018 | - | -$11.34 M(+86.7%) | -$34.87 M(+9.5%) |
| Dec 2017 | -$31.84 M(-29.0%) | -$6.07 M(-25.4%) | -$31.84 M(-9.1%) |
| Sept 2017 | - | -$8.14 M(-12.7%) | -$35.01 M(-3.5%) |
| June 2017 | - | -$9.32 M(+12.1%) | -$36.27 M(-4.6%) |
| Mar 2017 | - | -$8.31 M(-10.0%) | -$38.00 M(-15.3%) |
| Dec 2016 | -$44.85 M(-10.1%) | -$9.24 M(-1.6%) | -$44.85 M(-11.3%) |
| Sept 2016 | - | -$9.39 M(-15.1%) | -$50.55 M(-6.8%) |
| June 2016 | - | -$11.06 M(-27.1%) | -$54.24 M(-2.4%) |
| Mar 2016 | - | -$15.16 M(+1.5%) | -$55.60 M(+11.5%) |
| Dec 2015 | -$49.88 M(+26.1%) | -$14.94 M(+14.2%) | -$49.88 M(+12.7%) |
| Sept 2015 | - | -$13.08 M(+5.4%) | -$44.26 M(+11.0%) |
| June 2015 | - | -$12.42 M(+31.5%) | -$39.88 M(+3.8%) |
| Mar 2015 | - | -$9.44 M(+1.4%) | -$38.41 M(-2.9%) |
| Dec 2014 | -$39.56 M(+24.4%) | -$9.31 M(+7.1%) | -$39.56 M(+1.0%) |
| Sept 2014 | - | -$8.70 M(-20.5%) | -$39.17 M(+2.7%) |
| June 2014 | - | -$10.95 M(+3.4%) | -$38.13 M(+9.4%) |
| Mar 2014 | - | -$10.59 M(+18.6%) | -$34.86 M(+9.7%) |
| Dec 2013 | -$31.79 M(+58.3%) | -$8.93 M(+16.6%) | -$31.79 M(+13.3%) |
| Sept 2013 | - | -$7.66 M(-0.3%) | -$28.05 M(+10.2%) |
| June 2013 | - | -$7.68 M(+2.2%) | -$25.45 M(+16.9%) |
| Mar 2013 | - | -$7.52 M(+44.8%) | -$21.76 M(+8.4%) |
| Dec 2012 | -$20.08 M(+38.0%) | -$5.19 M(+2.6%) | -$20.08 M(+6.2%) |
| Sept 2012 | - | -$5.06 M(+26.7%) | -$18.91 M(+6.9%) |
| June 2012 | - | -$3.99 M(-31.5%) | -$17.69 M(+5.7%) |
| Mar 2012 | - | -$5.83 M(+44.9%) | -$16.73 M(+15.0%) |
| Dec 2011 | -$14.56 M(+78.2%) | -$4.03 M(+4.9%) | -$14.56 M(+8.9%) |
| Sept 2011 | - | -$3.84 M(+26.3%) | -$13.36 M(+15.8%) |
| June 2011 | - | -$3.04 M(-16.9%) | -$11.54 M(+11.5%) |
| Mar 2011 | - | -$3.65 M(+29.1%) | -$10.35 M(+26.7%) |
| Dec 2010 | -$8.17 M(+89.0%) | -$2.83 M(+40.5%) | -$8.17 M(+31.6%) |
| Sept 2010 | - | -$2.01 M(+9.1%) | -$6.21 M(+9.4%) |
| June 2010 | - | -$1.85 M(+25.1%) | -$5.68 M(+19.1%) |
| Mar 2010 | - | -$1.48 M(+69.3%) | -$4.77 M(+10.4%) |
| Dec 2009 | -$4.32 M(+75.4%) | -$872.20 K(-41.2%) | -$4.32 M(-10.3%) |
| Sept 2009 | - | -$1.48 M(+58.4%) | -$4.82 M(+41.5%) |
| June 2009 | - | -$936.50 K(-9.0%) | -$3.40 M(+5.7%) |
| Mar 2009 | - | -$1.03 M(-24.9%) | -$3.22 M(+30.7%) |
| Dec 2008 | -$2.46 M | -$1.37 M(+1882.9%) | -$2.46 M(+69.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2008 | - | -$69.10 K(-90.8%) | -$1.45 M(-5.5%) |
| June 2008 | - | -$753.20 K(+177.3%) | -$1.54 M(+35.5%) |
| Mar 2008 | - | -$271.60 K(-24.4%) | -$1.13 M(-9.0%) |
| Dec 2007 | -$1.25 M(-2.1%) | -$359.20 K(+134.0%) | -$1.25 M(+15.2%) |
| Sept 2007 | - | -$153.50 K(-56.1%) | -$1.08 M(-7.7%) |
| June 2007 | - | -$350.00 K(-8.8%) | -$1.17 M(+28.5%) |
| Mar 2007 | - | -$383.70 K(+97.3%) | -$911.80 K(-28.4%) |
| Dec 2006 | -$1.27 M(-10.0%) | -$194.50 K(-20.3%) | -$1.27 M(+74.5%) |
| Sept 2006 | - | -$243.90 K(+171.9%) | -$729.50 K(-36.4%) |
| June 2006 | - | -$89.70 K(-88.0%) | -$1.15 M(-23.6%) |
| Mar 2006 | - | -$744.80 K(-313.5%) | -$1.50 M(+6.1%) |
| Dec 2005 | -$1.41 M(-8.0%) | $348.90 K(-152.8%) | -$1.41 M(-27.9%) |
| Sept 2005 | - | -$660.80 K(+49.1%) | -$1.96 M(+32.3%) |
| June 2005 | - | -$443.20 K(-32.7%) | -$1.48 M(+3.9%) |
| Mar 2005 | - | -$659.00 K(+232.7%) | -$1.43 M(-7.2%) |
| Dec 2004 | -$1.54 M(+134.9%) | -$198.10 K(+8.7%) | -$1.54 M(-14.8%) |
| Sept 2004 | - | -$182.30 K(-52.9%) | -$1.80 M(+65.5%) |
| June 2004 | - | -$387.00 K(-49.7%) | -$1.09 M(+26.3%) |
| Mar 2004 | - | -$769.30 K(+65.7%) | -$862.60 K(+31.9%) |
| Dec 2003 | -$654.10 K(-69.3%) | -$464.40 K(-187.4%) | -$654.20 K(-6.9%) |
| Sept 2003 | - | $531.10 K(-431.9%) | -$702.60 K(-58.6%) |
| June 2003 | - | -$160.00 K(-71.5%) | -$1.70 M(-16.1%) |
| Mar 2003 | - | -$560.90 K(+9.4%) | -$2.02 M(-4.9%) |
| Dec 2002 | -$2.13 M(-33.7%) | -$512.80 K(+10.3%) | -$2.13 M(+12.0%) |
| Sept 2002 | - | -$464.90 K(-4.4%) | -$1.90 M(-25.2%) |
| June 2002 | - | -$486.20 K(-26.9%) | -$2.54 M(-11.3%) |
| Mar 2002 | - | -$665.30 K(+134.3%) | -$2.87 M(-10.8%) |
| Dec 2001 | -$3.21 M(-34.3%) | -$284.00 K(-74.3%) | -$3.21 M(-15.2%) |
| Sept 2001 | - | -$1.11 M(+36.3%) | -$3.79 M(-1.6%) |
| June 2001 | - | -$811.40 K(-19.9%) | -$3.85 M(-10.4%) |
| Mar 2001 | - | -$1.01 M(+18.0%) | -$4.30 M(-12.1%) |
| Dec 2000 | -$4.89 M(+7.3%) | -$858.50 K(-26.4%) | -$4.89 M(-9.2%) |
| Sept 2000 | - | -$1.17 M(-7.5%) | -$5.39 M(+14.1%) |
| June 2000 | - | -$1.26 M(-21.5%) | -$4.72 M(-4.8%) |
| Mar 2000 | - | -$1.61 M(+18.3%) | -$4.96 M(+8.9%) |
| Dec 1999 | -$4.56 M(+117.0%) | -$1.36 M(+171.3%) | -$4.56 M(+42.4%) |
| Sept 1999 | - | -$500.00 K(-66.7%) | -$3.20 M(-17.9%) |
| June 1999 | - | -$1.50 M(+25.0%) | -$3.90 M(+14.7%) |
| Mar 1999 | - | -$1.20 M(0.0%) | -$3.40 M(-27.7%) |
| Dec 1998 | -$2.10 M(-53.3%) | - | - |
| Sept 1998 | - | -$1.20 M(+20.0%) | -$4.70 M(+4.4%) |
| June 1998 | - | -$1.00 M(-16.7%) | -$4.50 M(+50.0%) |
| June 1998 | -$4.50 M(+246.2%) | - | - |
| Mar 1998 | - | -$1.20 M(-7.7%) | -$3.00 M(+20.0%) |
| Dec 1997 | - | -$1.30 M(+30.0%) | -$2.50 M(+47.1%) |
| Sept 1997 | - | -$1.00 M(-300.0%) | -$1.70 M(+30.8%) |
| June 1997 | -$1.30 M(-38.1%) | $500.00 K(-171.4%) | -$1.30 M(-27.8%) |
| Mar 1997 | - | -$700.00 K(+40.0%) | -$1.80 M(+63.6%) |
| Dec 1996 | - | -$500.00 K(-16.7%) | -$1.10 M(+83.3%) |
| Sept 1996 | - | -$600.00 K(0.0%) | -$600.00 K(-72.7%) |
| June 1996 | -$2.10 M(0.0%) | - | - |
| Sept 1995 | - | -$600.00 K(+50.0%) | -$2.20 M(+4.8%) |
| June 1995 | -$2.10 M(+31.3%) | -$400.00 K(-20.0%) | -$2.10 M(-8.7%) |
| Mar 1995 | - | -$500.00 K(-28.6%) | -$2.30 M(+9.5%) |
| Dec 1994 | - | -$700.00 K(+40.0%) | -$2.10 M(+16.7%) |
| Sept 1994 | - | -$500.00 K(-16.7%) | -$1.80 M(+12.5%) |
| June 1994 | -$1.60 M(+23.1%) | -$600.00 K(+100.0%) | -$1.60 M(+14.3%) |
| Mar 1994 | - | -$300.00 K(-25.0%) | -$1.40 M(0.0%) |
| Dec 1993 | - | -$400.00 K(+33.3%) | -$1.40 M(+7.7%) |
| Sept 1993 | - | -$300.00 K(-25.0%) | -$1.30 M(0.0%) |
| June 1993 | -$1.30 M(+116.7%) | -$400.00 K(+33.3%) | -$1.30 M(+44.4%) |
| Mar 1993 | - | -$300.00 K(0.0%) | -$900.00 K(+50.0%) |
| Dec 1992 | - | -$300.00 K(0.0%) | -$600.00 K(+100.0%) |
| Sept 1992 | - | -$300.00 K | -$300.00 K |
| June 1992 | -$600.00 K | - | - |
FAQ
- What is Lineage Cell Therapeutics annual free cash flow?
- What is the all time high annual FCF for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual FCF year-on-year change?
- What is Lineage Cell Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly FCF year-on-year change?
- What is Lineage Cell Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM FCF year-on-year change?
What is Lineage Cell Therapeutics annual free cash flow?
The current annual FCF of LCTX is -$29.24 M
What is the all time high annual FCF for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual free cash flow is $646.00 K
What is Lineage Cell Therapeutics annual FCF year-on-year change?
Over the past year, LCTX annual free cash flow has changed by -$29.89 M (-4626.32%)
What is Lineage Cell Therapeutics quarterly free cash flow?
The current quarterly FCF of LCTX is -$5.90 M
What is the all time high quarterly FCF for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly free cash flow is $21.86 M
What is Lineage Cell Therapeutics quarterly FCF year-on-year change?
Over the past year, LCTX quarterly free cash flow has changed by -$723.00 K (-13.97%)
What is Lineage Cell Therapeutics TTM free cash flow?
The current TTM FCF of LCTX is -$23.06 M
What is the all time high TTM FCF for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM free cash flow is $5.39 M
What is Lineage Cell Therapeutics TTM FCF year-on-year change?
Over the past year, LCTX TTM free cash flow has changed by +$8.36 M (+26.61%)